सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation(Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/22/000091 Dated 07-Nov-2022

To,
M/s Eli Lilly and Company (India) Pvt. Ltd.,
Plot No 92, Sector 32, Institutional Area,
Gurugram, Haryana(India) - 122001

Subject: Application for grant of permission to conduct Phase IV clinical trial entitled – "A 24-week multicenter, open-label, single-arm study to evaluate safety in patients with type 2 diabetes mellitus in India treated with Dulaglutide" as per Protocol No.: H9X-IN-GBGR, Amendment No.: H9X-IN-GBGR(a) Date: 16 Sep 2022- regarding

Ref.:Your Application No. BIO/CT04/FF/2022/33278 dated 12-Aug-2022

Sir,

With reference to your Application No.: BIO/CT04/FF/2022/33278 dated 12-Aug-2022, please find enclosed herewith the permission in Form CT-06 for conduct of subject Phase IV clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

(I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;

(II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;

(IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;

(X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;

(XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;

(XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

Yours faithfully,

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=112046a34e21727bacb255748732c456d249073e55e953d9cb5b58748ee3113c, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: [illegible]

(Dr. V.G. Somani)
Drugs Controller General (India)

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits M/s Eli Lilly and Company (India) Pvt. Ltd.,Plot No 92, Sector 32, Institutional Area,Gurugram, Haryana(India) – 122001 to conduct clinical trial of the new drug or investigational new drug study titled “A 24-week multicenter, open-label, single-arm study to evaluate safety in patients with type 2 diabetes mellitus in India treated with Dulaglutide” as per Protocol No.: H9X-IN-GBGR, Amendment No.: H9X-IN-GBGR(a) Date: 16 Sep 2022 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 07-Nov-2022

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=112046a34e21727bacb255748732c456d249073e55e953d9cb5b58748ee3113c, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.11.09 12:09:07 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	1. Dulaglutide Solution for injection (r-DNA origin) 0.75 mg/0.5 mL in a prefilled pen 2. Dulaglutide Solution for injection (r-DNA origin) 1.5 mg/0.5 mL in a prefilled pen
Therapeutic class:	Antidiabetic
Dosage form:	Solution for Injection
Composition:	

Name of Ingredients	Quantity per 0.5 ml	Quantity per 0.5 ml
Dulaglutide IH	0.75	1.5
Trisodium Citrate Dihydrate USP/Ph.Eur/JP	1.37	1.37
Citric acid anhydrous USP/Ph.Eur/JP	0.07	0.07
Mannitol USP/Ph.Eur/JP	23.2	23.2
Polysorbate 80 NF/Ph.Eur/JP	0.10	0.10
Water for Injection USP/Ph.Eur/JP	q.s to 0.5ml	q.s to 0.5ml

Indications:	Dulaglutide is indicated in adults with type 2 Diabetes Mellitus to improve glycaemic control as: Monotherapy- When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.(The recommended dose is 0.75mg once weekly Add-on therapy- In combination with other glucose-lowering medicinal products including insulin when these together with diet and exercise, do not provide adequate glycaemic control. (The recommended dose is 1.5mg once weekly)

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Lifepoint Multispecialty Hospital,145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad,Pune-411057, Maharashtra, India	LPR Ethics Committee,Lifepoint Multispecialty Hospital, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune-411057, Maharashtra,India EC Reg no: ECR/751/Inst/MH/2015/RR-21	Dr. Dange Amol Laxmanrao
2	Diacare Research,1-2, Gandhi Park, Near Nehrunagar Cross Road, Ambawadi, Ahmedabad-380015, Gujarat, India	Shrey Hospital Institutional ethics Committee,Shrey Hospital Private Limited 270/5/B, Near AMCO Bank, Stadium Circle, Navrangpura, Ahmedabad - 380009, Gujarat, India EC Reg no: ECR/1302/Inst/GJ/2019	Dr. Saboo Banshi Damodarlal
3	Virinchi Hospitals,Door No. 6-3-2, 3,311, Road No.1, Banjara Hills, Hyderabad - 500034,Telangana, India	Virinchi Hospitals Institutional Ethics Committee,Door No. 6-3-2, 3,311, Road No.1, Banjara Hills, Hyderabad - 500034,Telangana, India EC Reg no: ECR/993/Inst/AP/2017/RR-20	Dr Ahrar Ahmed Feroz

4	Grant Govt. Medical College and Sir J J Group of Hospital, Byculla, Mumbai – 400008. Maharashtra, India	Institutional Ethics Committee, GGMC, Mumbai ,Grant Govt. Medical College and Sir J J Group of Hospital, Byculla, Mumbai – 400008. Maharashtra, India EC Reg no: ECR/382/Inst/MH/2013/RR-19	Dr Gupta Hemant Ramsharam
5	Bhandari Clinic & Research Center,D-126, Krishna Marg, Bapu Nagar, Jaipur 302015, Rajasthan, India	IEC, Jaipur National University Institute for Medical Sciences & Research Center,First Flooor, Admin Block, JNU Hospital, Jagatpura, Jaipur-302017, Rajasthan, India EC Reg no:ECR/905/Inst/RJ/2017/RR-20	Dr. Sudhir Bhandari
6	V.S. General Hospital,Ellisbridge, Ahmedabad -380006, Gujarat, India	Shrey Hospital Institutional ethics Committee,Shrey Hospital Private Limited 270/5/B, Near AMCO Bank, Stadium Circle, Navrangpura, Ahmedabad - 380009, Gujarat, India EC Reg no: ECR/1302/Inst/GJ/2019	Dr. Shukla Dhaiwat Mruheshbhai
7	Medical College Kolkata,88, College Street Kolkata - 700073, West Bengal, India	Institutional Ethics Committee for Human Research Medical college, 88, College Street Kolkata -700073, West Bengal, India EC Reg no: ECR/287/Inst/WB/2013/RR-19	Dr Animesh Maiti
8	Amrita Institute of Medical Sciences and Research Centre,AIMS-Ponekkara.P.O, Kochi - 682041, Kerala, India	Institutional Ethics committee, Amrita Institute of Medical Sciences, AIMS-Ponekkara Kochi Edappally, Ernakulam, Kerala-682041, India EC Reg no: ECR/129/Inst/KL/2013/RR-19	Dr Harish Kumar
9	Government Medical College,Department of General Medicine, Government Medical College, Kozhikode-673008, Kerala, India	Insitutional Ethics Committee, 4th floor, Golden Jubilee Annex Institute of Maternal and child Health, Government Medical College, Kozhikode-673008, Kerala India EC Reg no: ECR/395/Inst/KL/2013/RR-20	Dr Rojith KB
10	Kovai Diabetes Speciality Centre and Hospital,No.15, Vivekananda Road, Ramnagar, Coimbatore-641 009, Tamilnadu, India	Institutional Ethics Committee of Kovai Diabetes Speciality Centre & Hospital,No.15, Vivekananda Road, Ramnagar, Coimbatore-641 009, Tamilnadu, India EC Reg no: ECR/233/Inst/TN/2013/RR-19	Dr Balamurugan Ramanathan
11	Lifecare Hospital and Research Center,2748/2152, M.L. N Enclave,16th 'E' Cross Road, 8th main, D block, Next to Union Bank, Sahakarnagar, Bengaluru - 560092, Karnataka, India	Lifecare Hospital Institutional Review Board,#2748/2152, M.L. N Enclave,16th 'E' Cross Road, 8th main, D block, Next to Union Bank, Sahakarnagar, Bengaluru - 560092, Karnataka, India EC Reg no: ECR/883/Inst/KA/2017/RR-20	Dr L.Sreenivasamurthy

12	Nil Ratan Sircar Medical College and Hospital,138, AJC Bose Road, Kolkata-700014, West Bengal, India	Ethics Committee, N.R.S Medical College,Nil Ratan Sircar Medical College and Hospital, 138, AJC Bose Road, Kolkata-700014, West Bengal, India EC Reg no: ECR/609/Inst/WB/2014/RR-20	Dr Arjun Baidya

CENTRAL DRUGS STANDARD CONTROL ORGANISATION
CDSCO CDSCO
सत्यमेव जयते
MINISTRY OF HEALTH, GOVERNMENT OF INDIA